Cargando…
Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium‐specific FAK‐kinase dead mice
Focal adhesion kinase (FAK) inhibitors have been developed as potential anticancer agents and are undergoing clinical trials. In vitro activation of the FAK kinase domain triggers autophosphorylation of Y397, Src activation, and subsequent phosphorylation of other FAK tyrosine residues. However, how...
Autores principales: | Alexopoulou, Annika N, Lees, Delphine M, Bodrug, Natalia, Lechertier, Tanguy, Fernandez, Isabelle, D'Amico, Gabriela, Dukinfield, Matthew, Batista, Silvia, Tavora, Bernardo, Serrels, Bryan, Hodivala‐Dilke, Kairbaan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518444/ https://www.ncbi.nlm.nih.gov/pubmed/28444899 http://dx.doi.org/10.1002/path.4911 |
Ejemplares similares
-
FAK-heterozygous mice display enhanced tumour angiogenesis
por: Kostourou, Vassiliki, et al.
Publicado: (2013) -
Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth
por: Lechertier, Tanguy, et al.
Publicado: (2020) -
Endothelial FAK is required for tumour angiogenesis
por: Tavora, Bernardo, et al.
Publicado: (2010) -
Endothelial FAK is required for tumour angiogenesis
por: Tavora, Bernardo, et al.
Publicado: (2016) -
Author Correction: Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth
por: Lechertier, Tanguy, et al.
Publicado: (2023)